Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Combination signal transduction inhibition: a phase 1 and 2 trial of the oral mTOR-inhibitor everolimus (ERAD001) and imatinib mesylate (IM, Glivac r/Gleevac r) in patients (pts) with gastrointestinal stromal tumor (GIST) refactory to IM

Combination signal transduction inhibition: a phase 1 and 2 trial of the oral mTOR-inhibitor everolimus (ERAD001) and imatinib mesylate (IM, Glivac r/Gleevac r) in patients (pts) with gastrointestinal stromal tumor (GIST) refactory to IM. American Society of Clinical Oncology (ASCO) Conference. 2004.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.